OKUR Stock Summary and Trading Ideas (Onkure Therapeutics - Class A | NASDAQ:OKUR)

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Ka. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Onkure Therapeutics - Class A trades on the NASDAQ stock market under the symbol OKUR.

As of August 3, 2026, OKUR stock price climbed to $4.02 with 155,012 million shares trading.

OKUR has a beta of 0.77, meaning it tends to be less sensitive to market movements. OKUR has a correlation of 0.02 to the broad based SPY ETF.

OKUR has a market cap of $162.39 million. This is considered a Micro Cap stock.

Last quarter Onkure Therapeutics - Class A reported $0 in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-200,000 and missed earnings estimates by -$.35.

The top ETF exchange traded funds that OKUR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

OKUR has outperformed the market in the last year with a return of +82.7%, while the SPY ETF gained +23.1%. However, in the most recent history, OKUR shares have underperformed the stock market with its stock returning -15.0% in the last 3 month period and -2.4% for the last 2 week period, while SPY has returned +5.4% and +2.1%, respectively.

OKUR support price is $3.63 and resistance is $4.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKUR shares will trade within this expected range on the day.